7th Annual European Antibody Congress 2011

EB66 cell line, a duck embryonic stem cell-derived substrate for the industrial production of therapeutic monoclonal antibodies with enhanced ADCC activity

(2014) Stéphane Olivier et al.   mAbs

Antitumor Efficacy of a Thrombospondin 1 Mimetic CovX-Body

(2014) Lingna Li et al.   Translational Oncology

Which are the antibodies to watch in 2012?

(2012) Janice M. Reichert   mAbs

Tetraspanin CD151 as a target for antibody-based cancer immunotherapy

(2011) Jean-François Haeuw et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

A biosimilar industry view on the implementation of the WHO guidelines on evaluating similar biotherapeutic products

(2011) Martin Schiestl   BIOLOGICALS

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

(2011) W. Alduaij et al.   BLOOD

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

(2011) G. Niederfellner et al.   BLOOD

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy

(2011) S. H. Lim et al.   BLOOD

Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII)

(2011) Katja Klausz et al.   CANCER SCIENCE

Angiopoietin-2 TIEs Up Macrophages in Tumor Angiogenesis: Figure 1.

(2011) Michele De Palma et al.   CLINICAL CANCER RESEARCH

Specifically Targeting Angiopoietin-2 Inhibits Angiogenesis, Tie2-Expressing Monocyte Infiltration, and Tumor Growth

(2011) H. Huang et al.   CLINICAL CANCER RESEARCH

Investigational antibody drug conjugates for solid tumors

(2011) Puja Sapra et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Recombinant Dimeric IgA Antibodies against the Epidermal Growth Factor Receptor Mediate Effective Tumor Cell Killing

(2011) S. Lohse et al.   JOURNAL OF IMMUNOLOGY

Evolution of Potent and Stable Placental-Growth-Factor-1-Targeting CovX-Bodies from Phage Display Peptide Discovery

(2011) Kristen E. Bower et al.   JOURNAL OF MEDICINAL CHEMISTRY

HuCAL PLATINUM, a Synthetic Fab Library Optimized for Sequence Diversity and Superior Performance in Mammalian Expression Systems

(2011) Josef Prassler et al.   JOURNAL OF MOLECULAR BIOLOGY

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

(2011) Robert Pirker et al.   LANCET ONCOLOGY

Worldwide experience with biosimilar development

(2011) Mark McCamish et al.   mAbs

Next generation and biosimilar monoclonal antibodies: Essential considerations towards regulatory acceptance in Europe; February 3-4, 2011; Freiburg, Germany

(2011) Janice M. Reichert   mAbs

Comparability analysis of protein therapeutics by bottom-up LC-MS with stable isotope-tagged reference standards

(2011) Anton V. Manuilov et al.   mAbs

6thAnnual European Antibody Congress 2010

(2011) Alain Beck et al.   mAbs

Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors

(2011) Chong Wang et al.   mAbs

Rational engineering of antibody therapeutics targeting multiple oncogene pathways

(2011) Jonathan Fitzgerald et al.   mAbs

Bispecific antibodies and ADCs

(2011) Janice M. Reichert   mAbs

World Antibody Drug Conjugate Summit Europe

(2011) Alain Beck et al.   mAbs

Biosimilar, biobetter and next generation therapeutic antibodies

(2011) Alain Beck   mAbs

The amazing, multipurpose antibody

(2011) Alain Beck et al.   mAbs

Monoclonal antibodies in neuro-oncology

(2011) Lois A. Lampson   mAbs

Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study

(2011) Ningyan Zhang et al.   mAbs

Antibody-based therapeutics to watch in 2011

(2011) Janice M. Reichert   mAbs

Rapid LC–MS screening for IgG Fc modifications and allelic variants in blood

(2011) Andrew M. Goetze et al.   MOLECULAR IMMUNOLOGY

Acceptable changes in quality attributes of glycosylated biopharmaceuticals

(2011) Martin Schiestl et al.   NATURE BIOTECHNOLOGY

Anti-galactose-α-1,3-galactose IgE from allergic patients does not bind α-galactosylated glycans on intact therapeutic antibody Fc domains

(2011) Jeroen J Lammerts van Bueren et al.   NATURE BIOTECHNOLOGY

Biosimilars—why terminology matters

(2011) Martina Weise et al.   NATURE BIOTECHNOLOGY

How were new medicines discovered?

(2011) David C. Swinney et al.   NATURE REVIEWS DRUG DISCOVERY

Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies

(2011) W. Schaefer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Bispecific digoxigenin-binding antibodies for targeted payload delivery

(2011) S. Metz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc RIII and antibodies lacking core fucose

(2011) C. Ferrara et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses

(2011) D. C. Ekiert et al.   SCIENCE

Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma

(2010) Hans-Peter Gerber   BIOCHEMICAL PHARMACOLOGY

Design and Application of Antibody Cysteine Variants

(2010) Vladimir Voynov et al.   BIOCONJUGATE CHEMISTRY

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

(2010) E. Mossner et al.   BLOOD

Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells

(2010) Michaela Patz et al.   BRITISH JOURNAL OF HAEMATOLOGY

Superior In vivo Efficacy of Afucosylated Trastuzumab in the Treatment of HER2-Amplified Breast Cancer

(2010) Teemu T. Junttila et al.   CANCER RESEARCH

Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) againstKRAS-mutated tumor cells

(2010) Martin Schlaeth et al.   CANCER SCIENCE

Laminin-binding integrins and their tetraspanin partners as potential antimetastatic targets

(2010) Christopher S. Stipp   EXPERT REVIEWS IN MOLECULAR MEDICINE

Structure-Function Analysis of Tetraspanin CD151 Reveals Distinct Requirements for Tumor Cell Behaviors Mediated by α3β1versusα6β4 Integrin

(2010) Shannin Zevian et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Combined use of immunoassay and two-dimensional liquid chromatography mass spectrometry for the detection and identification of metabolites from biotherapeutic pharmacokinetic samples

(2010) Robert E. Murphy et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Prediction of Aggregation Prone Regions of Therapeutic Proteins

(2010) Naresh Chennamsetty et al.   JOURNAL OF PHYSICAL CHEMISTRY B

Americas Antibody Congress

(2010) Susan E. Lacy et al.   mAbs

Sensitivity and resistance to EGF-R inhibitors

(2010) Matthias Peipp et al.   mAbs

European Medicines Agency workshop on biosimilar monoclonal antibodies

(2010) Janice M. Reichert et al.   mAbs

Antibody drug-conjugates targeting the tumor vasculature

(2010) Hans-Peter Gerber et al.   mAbs

Enhanced antibody half-life improves in vivo activity

(2010) Jonathan Zalevsky et al.   NATURE BIOTECHNOLOGY

Chemical generation of bispecific antibodies

(2010) V. R. Doppalapudi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Epitope mapping and key amino acid identification of anti-CD22 immunotoxin CAT-8015 using hybrid  -lactamase display

(2010) D. Bannister et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Prediction of protein binding regions

(2010) Naresh Chennamsetty et al.   PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS

Probing deamidation in therapeutic immunoglobulin gamma (IgG1) by ‘bottom-up’ mass spectrometry with electron transfer dissociation

(2010) Raju Mukherjee et al.   RAPID COMMUNICATIONS IN MASS SPECTROMETRY

CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies

(2010) Stephen A. Beers et al.   SEMINARS IN HEMATOLOGY

The Human Endogenous Retrovirus Link between Genes and Environment in Multiple Sclerosis and in Multifactorial Diseases Associating Neuroinflammation

(2009) Hervé Perron et al.   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

American Society of Clinical Oncology Provisional Clinical Opinion: Testing forKRASGene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy

(2009) Carmen J. Allegra et al.   JOURNAL OF CLINICAL ONCOLOGY

Serum-free production and purification of chimeric IgA antibodies

(2009) T. Beyer et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage

(2009) Tanja Schneider-Merck et al.   JOURNAL OF IMMUNOLOGY

Aggregation-Prone Motifs in Human Immunoglobulin G

(2009) Naresh Chennamsetty et al.   JOURNAL OF MOLECULAR BIOLOGY

Electrospray ionization quadrupole ion-mobility time-of-flight mass spectrometry as a tool to distinguish the lot-to-lot heterogeneity in N-glycosylation profile of the therapeutic monoclonal antibody trastuzumab

(2009) Carola W. N. Damen et al.   JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY

The TLR3 signaling complex forms by cooperative receptor dimerization

(2008) J. N. Leonard et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA